# Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers

> **NCT02149095** · PHASE1 · WITHDRAWN · sponsor: **United Therapeutics**

## Conditions studied

- PAH

## Interventions

- **DRUG:** TransCon PEG treprostinil

## Key facts

- **NCT ID:** NCT02149095
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-07
- **Primary completion:** 2014-11
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study will not be conducted
- **Last updated:** 2014-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02149095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02149095, "Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02149095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*